BÖLÜM 12

JİNEKOLOJİK KANSERLERDE KEMOTERAPİ VE HEMŞİRELİK BAKIMI

Simge EVRENOL ÖÇAL[1]
Nuray EGELİOĞLU CETİŞLİ[2]

GİRİŞ

Vücuttaki tüm kanser hücrelerini ve metastazları hedef alması temeline dayanan kemoterapi, normal hücreleri de etkileyen sistemik bir terapötik ajan olarak kullanılmaktadır [(1)]. Kanser tedavisinde kemoterapi, etkili bir alternatif tedavinin bulunmadığı veya alternatif tedavinin idealin altında olduğu kanserler için birincil tedavi olarak kabul edilmektedir [(2)]. Bu nedenle jinekolojik kanserlerin tedavisinde kullanılan başlıca tedavi yöntemlerinden biridir. Diğer kemoterapi tedavilerinde olduğu gibi jinekolojik kanserlerde kemoterapi alan hastaların da bakım gereksinimlerinin karşılanması hastalığın tedavisi kadar önem taşımaktadır. Jinekolojik kanserlerde kemoterapiye yönelik hemşirelik bakımı kemoterapi kararının alınması ile başlayan ve hastalığın seyrine ve kadının ihtiyaçlarına göre değişiklik gösteren aktif bir süreçtir [(1,2)]. Kadın ve ailesinin hastalık ve tedaviye ilişkin eğitimi, kemoterapi uygulaması ve kullanılan kemoterapötik rejimin toksisite belirtilerinin yönetimi, jinekolojik kanser tedavisinde yaygın olarak kullanılmaya başlanan intraperitoneal kemoterapide hemşirelik bakımı bu bölümde ele alınan konulardır.

[1] Dr. Öğr. İzmir Kâtip Çelebi Üniversitesi, Sağlık Bilimleri Fakültesi/Kadın Hastalıkları ve Doğum Hemşireliği AD, simge.evrenol.ocal@gmail.com

[2] Doç. Dr., İzmir Kâtip Çelebi Üniversitesi, Sağlık Bilimleri Fakültesi, Kadın Hastalıkları ve Doğum Hemşireliği AD, nurayegelioglu@gmail.com

KAYNAKLAR

1. Charnay-Sonnek F,, Murphy AE. (2019). *Principle of nursing in oncology*. Springer.
2. Yarbro CH, Wujcik D, Gobel BH. (Eds.). (2011). *Cancer nursing*. (Seventh Edit). Jones & Bartlett Publishers.
3. Esper P, Gilmore TR, Jacobson JO. 2013 Updated American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards Including Standards for the Safe Administration and Management of Oral Chemotherapy. In Oncology Nursing Forum. 2013;40(3),225.
4. Olsen M, LeFebvre K, Brassil K. (2018). *Chemotherapy and immunotherapy guidelines and recommendations for practice.* Oncology Nursing Society. s.261-268.
5. Neuss MN, Gilmore TR, Belderson KM, et al. 2016 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards, including standards for pediatric oncology. Journal of Oncology Practice. 2016;12(12), 1262-1271.
6. Olsen M. (Pittsburgh (Pennsylvania): Oncology Nursing Society. Chemotherapy. Julia Eggert (Ed.). *Cancer basics* (p.197-219). Pittsburgh (Pennsylvania): Oncology Nursing Society.
7. Bansavage N, Molasky W. (2020). Principles and Standards of Antineoplastic Therapy Administration. Mary gulatte, rowena schwartz, kathrine spinks, deborah kirk (Ed), *Clinical guide to antineoplastic therapy: a chemotherapy handbook* içinde (p.71-90). (Pittsburgh (Pennsylvania): Oncology Nursing Society.
8. Webster C, Roberts S, Gray DV, Mew C, et al. (2013). Gynaecology nursing oncology & palliative care guidelines. (03.05.2021 tarihinde http://www.nwcscnsenate.nhs.uk/files/4814/1319/7207/Gynae_Nursing_and_oncology_guidelinesCompleted_2013_-2016_guidelines.pdf adresinden ulaşılmıştır).
9. Tadman M, Roberts D, & Foulkes M. (Eds.). (2019). *Oxford handbook of cancer nursing.* (Second edit). Oxford University Press.
10. Esercan TY, Merih YD. Kemoterapide semptomların yönetimi. Zeynep Kamil Tıp Bülteni. 2010;41(1),35-42.
11. Drews RE. (2020). Causes of anemia in patients with cancer. UpToDate, Waltham, MA (26.05.2021 tarihinde https://www.uptodate.com/contents/causes-of-anemia-in-patients-with-cancer adresinden ulaşılmıştır).
12. Calabrich A, Katz A.Management of anemia in cancer patients. Future oncology. 2011;7(4),507-517.
13. Abdel-Razeq H, Hashem H. Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia. Critical reviews in oncology/hematology. 2020;145,102837.
14. Aapro M, Beguin Y, Bokemeyer C, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Annals of Oncology. 2018;29,iv96-iv110.
15. Rodgers GM, Becker PS, Blinder M, et al. Cancer-and chemotherapy-induced anemia. Journal of the National Comprehensive Cancer Network. 2012;10(5),628-653.
16. Michelson AD. (2019). The clinical approach to disorders of platelet number and

function. Michelson AD, Cattaneo M, Frelinger A, Newman P. (Ed), *Platelets* içinde (p.701-920). London: Elseiver Academic Press
17. Velcheti V, Punekar SR. (2021). *Handbook of Cancer Treatment-Related Symptoms and Toxicities E-Book.* Elsevier Health Sciences.
18. National Cancer Institude. (2017). Common terminology criteria for adverse events (CTCAE) v5.0. (24.06.2021 tarihinde https://ctep.cancer.gov/protocodevelopment/electronic_aplications/docs/ CTCAE_v5_Quick_Reference_8.5x11.pdf adresinden ulaşılmıştır).
19. Adams PL. (2017). Hematologic issues. Julia Eggert (Ed.). *Cancer basics* (491-504). Pittsburgh (Pennsylvania): Oncology Nursing Society.
20. Tarakçıoğlu Çelik GH. Nötropeni ve Hemşirelik Bakımı. *Sağlık ve Toplum,* 2016;26(2),10-16.
21. Amaral RAC, Oliveira PP, Fonseca DF, et al. Bundle for the prevention and management of complications of neutropenia in cancer patients. *Rev Bras Enferm.* 74(2):e20200195. Doi: http://doi.org/10.1590/0034-7167-2020-0195
22. Nirenberg A, Reame NK, Cato KD, et al. Oncology nurses' use of National Comprehensive Cancer Network clinical practice guidelines for chemotherapy-induced and febrile neutropenia. In Oncology nursing forum 2010;37(6):765-773.
23. Tarakçıoğlu Çelik GH, Korkmaz F. Nurses' knowledge and care practices for infection prevention in neutropenic patients. Contemp Nurse. 2017;53(2): 143-55. Doi:https://doi.org/10.1080/10376178.2016.1254566
24. Ying FLM, Ping MCY, Tong M, et al. A cohort study on protocol-based nurse-led out-patient management of postchemotherapy low-risk febrile neutropenia. *Support Care Cancer.* 26(9):3039-45. https://doi.org/10.1007/s00520-018-4157-6
25. Brown CG. (2015). *A guide to oncology symptom management.* (Second edit). Pittsburgh, PA: Oncology Nursing Society.
26. National Institude for Health and Cera Excellence (NICE). (2020). *2020 exceptional surveillance of neutropenic sepsis: prevention and management in people with cancer (NICE guideline CG151).* (02.06.2021 tarihinde https://www.nice.org.uk/guidance/cg151/resources/2020-exceptional-surveillance-of-neutropenic-sepsis-prevention-and-management-in-people-with-cancer-nice-guideline-cg151-pdf-9105603078085 adresinden ulaşılmıştır).
27. Bate J, Gibson F, Johnson E, et al. Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients (NICE Clinical Guideline CG151). Archives of Disease in Childhood-Education and Practice. 2013;98(2),73-75.
28. Gupta K, Walton R, Kataria SP. Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Recommendations, and New Trends. Cancer *Treatment and Research Communications,* 26:100278. doi: 10.1016/j.ctarc.2020.100278.
29. Aapro M. CINV: still troubling patients after all these years, Support Care Cancer. 2018;26 (Suppl 1),5–9.
30. Navari RM. Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting. *BioMed research international 2015,* 1-6. Doi: https://doi.org/10.1155/2015/595894

31. Barsevick AM. (2015). *A Guide to Oncology Symptom Management.* (Second Edit). Pittsburgh (Pennsylvania): Oncology Nursing Society.
32. Dunphy, EP. (2017). Gastrointestinal symptoms. Julia Eggert (Ed.). *Cancer basics* (431-473). Pittsburgh (Pennsylvania): Oncology Nursing Society.
33. Matzo M, Sherman DW. (2018). *Palliative care nursing: Quality care to the end of life.* (Fifth edit). Springer Publishing Company.
34. National Comprehensive Cancer Network (NCCN). (2016). *NCCN guidelines for patients. Nausea and vomiting. Version 1.2016.* (30.05.2021 tarihinde https://www.nccn.org/patients/guidelines/content/PDF/nauseapatient.pdf adresinden ulaşılmıştır).
35. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology, 2017;35(28),3240-3261.
36. Hesketh, P. J. (2017). *Prevention and treatment of chemotherapy-induced nausea and vomiting in adults.* (24.05.2021 rarihinde https://www.uptodate.com/contents/prevention-and-treatment-of-chemotherapy-induced-nausea-and-vomiting-in-adults adresinden ulaşılmıştır).
37. Andreyev J, Ross P, Donnellan C, et al. Guidance on the management of diarrhoea during cancer chemotherapy. The Lancet Oncology, 2014;15(10),e447-e460.
38. Tarricone R, Koush DA, Nyanzi-Wakholi B, et al. A systematic literature review of the economic implications of chemotherapy-induced diarrhea and its impact on quality of life. Critical reviews in oncology/hematology. 2016;99,37-48.
39. Smith P, Lavery A, Turkington RC. An overview of acute gastrointestinal side effects of systemic anti-cancer therapy and their management. Best Practice & Research Clinical Gastroenterology. 2020;101691.
40. Kordes M, Gerling M. Variations in the management of diarrhoea induced by cancer therapy: results from an international, cross-sectional survey among European oncologists. ESMO open 2019;4(6),e000607.
41. de Lemos ML, Guenter J, Kletas V. Loperamide and cardiac events: Is high-dose use still safe for chemotherapy-induced diarrhea?. Journal of Oncology Pharmacy Practice. 2018;24(8),634-636.
42. Bossi P, Antonuzzo A, Cherny NI, et al. Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. Annals of Oncology. 2018;29,iv126-iv142.
43. Krishnamurthi SS, Macraon C. (2019). *Management of acute chemotherapy-related diarrhea.* (24.06.2021 tarihinde https://www.uptodate.com/contents/management-of-acute-chemotherapy-related-diarrhea adresinden ulaşılmıştır).
44. Kumar L, Harish P, Malik PS, et al. Chemotherapy and targeted therapy in the management of cervical cancer. Current problems in cancer. 2018;42(2),120-128.
45. Cibula D, Pötter R, Chiva L, et al. The European Society of Gynaecological Oncology / European Society for Radiotherapy and Oncology / European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer. International Journal of Gynaecological Cancer. 2018;28(4),641-655.
46. Padubidri VG, Daftary SN. (2014). *Shaw's Textbook of Gynecology E-Book.* Elsevier

Health Sciences.
47. Sun J, Wang H, Hu H. Glutamine for chemotherapy induced diarrhea: a meta-analysis. Asia Pac J Clin Nutr. 2012;21,380–385.
48. Cushing D, Joseph B. A low osmolarity rehydration solution that helps chemo patients. Journal of Medical Phyto Research. 2018;1(1),3-9.
49. Calixto-Lima L, de Andrade EM, Gomes AP, et al. Dietetic management in gastrointestinal complications from antimalignant chemotherapy. Nutricion hospitalaria. 2012;27(1),65-75.
50. Dunberger G, Lind H, Steineck G, et al. Loose stools lead to fecal incontinence among gynecological cancer survivors. Acta oncologica. 2011;50(2),233-242.
51. Dunberger G, Lind H, Steineck G, et al. Fecal incontinence affecting quality of life and social functioning among long-term gynecological cancer survivors. International Journal of Gynecologic Cancer. 2010;20(3),449-460.
52. Oncology Nursing Society (2020). *Manage cancer treatment-related constipation with ONS guidelines.* (15.06.2021 tarihinde https://voice.ons.org/news-and-views/manage-cancer-treatment-related-constipation-with-ons-guidelinestm adresinden ulaşılmıştır).
53. Rogers B, Ginex PK, Anbari A, et al. ONS guidelines™ for opioid-induced and non-opioid-related cancer constipation. Oncol Nurs Forum. 2020;47(6),671-691.
54. Larkin PJ, Cherny NI, La Carpia D, et al. Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. Annals of Oncology. 2018;29,iv111-iv125.
55. Kimura S, Hosoya K, Ogata K, et al. Severity of constipation related to palonosetron during first-line chemotherapy: A retrospective observational study. Supportive Care in Cancer. 2021;29,4723-4732.
56. McQuade RM, Stojanovska V, Abalo R, et al. Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments. Frontiers in Pharmacology. 2016;7,414.
57. Sivapornpan S, Suwannarurk K, Jaisin K, et al. Comparative study in quality of life between thai endometrial cancer survivors and healthy women in Thammasat University Hospital. Asian Pacific Journal of Cancer Prevention. 2020;21(1),249-254.
58. Elad S, Cheng KKF, Lalla RV, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020;126(19),4423-4431.
59. Nicolatou-Galitis O, Bossi P, Orlandi E, et al. The role of benzydamine in prevention and treatment of chemoradiotherapy-induced mucositis. *Supportive Care in Cancer*, 1-9. Doi: https://doi.org/10.1007/s00520-021-06048-5
60. Velcheti V, Punekar SR. (2021). *Handbook of Cancer Treatment-Related Symptoms and Toxicities E-Book.* Elsevier Health Sciences.
61. Kiki İ. Kemoterapiye Bağlı Mukozit. Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi. 2014;24(1),158-161.
62. Berk D. Kemoterapi Alan Kanser Hastalarında Mukozit Yönetimi. Sağlık ve Toplum. 2018;28(3),10-15.

63. Hong CH, Gueiros LA, Fulton JS, et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines. Supportive Care in Cancer. 2019;27(10),3949-3967.
64. Correa MEP, Cheng KKF, Chiang K, et al. Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines. Supportive Care in Cancer. 2019; 28:2449–2456.
65. Çubukçu NÜ, Çınar S. Kemoterapi alan kanserli hastalarda oral mukozitler önlenebilir mi?. Clinical and Experimental Health Sciences. 2012;2(4),155-163.
66. Chantragawe C, Achariyapota V. Utilization of a scored patient-generated subjective global assessment in detecting a malnourished status in gynecologic cancer patients. Asian Pacific Journal of Cancer Prevention. 2016;17(9),4401-4404.
67. Lee H, Choi-Kwon S. The relationships among chemotherapy-induced nausea and vomiting (CINV), non-pharmacological coping methods, and nutritional status in patients with gynecologic cancer. Journal of Korean Academy of Nursing. 2017;47(6),731-743.
68. Cantrell LA, Saks E, Grajales V, et al. Nutrition in gynecologic cancer. Current Obstetrics and Gynecology Reports. 2015;4(4),265-271.
69. National Comprehensive Cancer Network. (2011). NCCN *Clinical practice guidelines in oncology: Cancer-related fatigue*. (16.06.2021 tarihinde https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf adresinden ulaşılmıştır).
70. Al Maqbali M, Hughes C, Dunwoody L, et al. Exercise ınterventions to manage fatigue in women with gynecologic cancer: A systematic review. In Oncology Nursing Forum. 2019;46(1),71-83.
71. Wang XS, Woodruff JF. Cancer-related and treatment-related fatigue. Gynecologic Oncology. 2015;136(3),446-452.
72. Dikmen HA, Terzioglu F. Effects of reflexology and progressive muscle relaxation on pain, fatigue, and quality of life during chemotherapy in gynecologic cancer patients. Pain Management Nursing, 2019;20(1),47-53.
73. Gülüş Demirel B, Koca R, Solak Tekin N. Kemoterapi ekstravazasyonuna bağlı deri nekrozu ve selülit: Bir olgu sunumu. Turkish Journal of Oncology/Türk Onkoloji Dergisi. 2015;30(3),144-147.
74. Fidalgo JP, Fabregat LG, Cervantes A, et al. Margulies A, Vidall C, Roila F. (2012). Management of chemotherapy extravasation: ESMO–EONS clinical practice guidelines. European Journal of Oncology Nursing. 2012;16(5),528-534.
75. Viale PH. (2017). Dermatologic complications. Julia Eggert (Ed.). *Cancer basics* (397-409). Pittsburgh (Pennsylvania): Oncology Nursing Society.
76. Barbee MS, Owonikoko TK, Harvey RD. Taxanes: Vesicants, irritants, or just irritating? *Therapeutic Advances in Medical Oncology*, 6, 16–20. doi:10.1177/1758834013510546
77. Doellman D, Hadaway L, Bowe-Geddes LA et al. Infiltration and extravasation: update on prevention and management. Journal of Infusion Nursing. 2009;332(4),203-211.
78. Kähler KC, Mustroph D. Hauschild A. Current recommendations for prevention

and therapy of extravasation reactions in dermato-oncology. Journal of The German Society of Dermatology. 2009;7(1),21-28.
79. Reynolds PM, MacLaren R, Mueller SW, et al. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. Pharmacotherapy. 2014;34(6),617-632.
80. Arslan D, Aysever U, Deniz S, et al. Kemoterapi tedavi merkezine ilaç tedavisi için gelen hastalarda ekstravazasyon insidansı ve nedenleri. Dokuz Eylül Üniversitesi Hemşirelik Fakültesi Elektronik Dergisi. 2018;11(2),113-119.
81. Jackson-Rose J, Del Monte J, Groman A, et al. Chemotherapy Extravasation: establishing a national benchmark for incidence among Cancer Centers. Clinical journal of oncology nursing. 2017;21(4),438-445.
82. Sauerland C, Engelking C, Wickham R, et al. Vesicant extravasation part I: Mechanisms, pathogenesis, and nursing care to reduce risk. *Oncology Nursing Forum*, 33, 11341141. Doi: https://doi.org/10.1188/06.ONF.1134-1141.
83. Kim JT, Park JY, Lee HJ, et al. Guidelines for the management of extravasation. Journal of Educational evaluation for health professions. 2020;17:21.
84. Akaltun N, Zengi S, Macun S, et al. Meme kanserli bir hastada vinorelbin kemoterapisine bağlı ekstravazasyon. Uludağ Üniversitesi Tıp Fakültesi Dergisi. 2017;43(2),79-84.
85. Saxon M. (2017). Peripheral neuropathy. Julia Eggert (Ed.). *Cancer basics* (599-609). Pittsburgh (Pennsylvania): Oncology Nursing Society.
86. Staff NP, Grisold A, Grisold W, et al. Chemotherapy-induced peripheral neuropathy: A current review. *Annals* of Neurology, 81, 772–781. Doi: https://doi.org/10.1002/ana.24951.
87. Lavoie Smith EM, Zanville N. (2015). Chapter 21 Peripheral Neuropathy. Carlton G. Brown (Ed), *A Guide to Oncology Symptom Management* (Second Edit) içinde (p:531-549) Pittsburgh (Pennsylvania): Oncology Nursing Society
88. Molassiotis A, Suen LK, Cheng HL, et al. A randomized assessor-blinded wait-list-controlled trial to assess the effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy. Integrative cancer therapies. 2019;18,1534735419836501.
89. Jordan B, Margulies A, Cardoso F, et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Annals of Oncology. 2020;31(10),1306-1319.
90. Kayıkçı E E, Can G. Kanser hastalarında kemoterapi tedavisine bağlı gelişen periferal nöropatinin yönetiminde kanıta dayalı tamamlayıcı yaklaşımlar. HEAD 2020;17(1):59-65.
91. Hao J, Zhu X, Bensoussan A. Effects of Nonpharmacological Interventions in Chemotherapy-Induced Peripheral Neuropathy: An Overview of Systematic Reviews and Meta-Analyses. Integrative cancer therapies. 2020;19;1-23.
92. Smith TJ, Razzak AR, Blackford AL, et al. A pilot randomized sham-controlled trial of MC5-A scrambler therapy in the treatment of chronic chemotherapy-induced

peripheral neuropathy (CIPN). Journal of palliative care. 2020;35(1),53-58.
93. Viale, PH. (2017). Hypersensitivity. Julia Eggert (Ed.). *Cancer basics* (529-542). Pittsburgh (Pennsylvania): Oncology Nursing Society.
94. Roselló S, Blasco I, García Fabregat L, et al. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2017;28(suppl_4),iv100-iv118.
95. Levin AS, Bhattacharya G, Blumenthal K, et al. Platin chemotherapy hypersensitivity reactions: expanding the scope of practice and improving care. The Journal of Allergy and Clinical Immunology: In Practice. 2019;7(5),1691-1695.
96. Castells MC, Matulonis UA, Horton TM. (2020). *Infusion reactions to systemic chemotherapy.* (20.06.2021 tarihinde https://www.uptodate.com/contents/infusion-reactions-to-systemic-chemotherapy adresinden ulaşılmıştır).
97. Köycü G, Erkekol FÖ. (2016). Kemoterapötik Aşırı Duyarlılık Reaksiyonları. Meral Gülhan, Ülkü Yılmaz (Ed), *Akciğer kanserinde destek tedavisi* içinde (s. 275-286). İstanbul: Probiz Ltd. Şti.
98. Picard M, Pur L, Caiado J, et al. Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. *Journal of Allergy and Clinical Immunology*. 2016;137(4), 1154-1164.
99. Can G, Demir M, Erol O, et al. A comparison of men and women's experiences of chemotherapy-induced alopecia. European Journal of Oncology Nursing. 2013;17(3),255-260.
100. Boland V, Brady AM, Drury A. The physical, psychological and social experiences of alopecia among women receiving chemotherapy: An integrative literature review. European Journal of Oncology Nursing. 2020;49,101840.
101. Rossi A, Fortuna MC, Caro G, et al. Chemotherapy-induced alopecia management: Clinical experience and practical advice. Journal of Cosmetic Dermatology. 2017;16(4),537–541.
102. Ishida K, Ishida J, Kiyoko K. Psychosocial reaction patterns to alopecia in female patients with gynecological cancer undergoing chemotherapy. Asian Pacific Journal of Cancer Prevention. 2015;16(3),1225-1233.
103. Fehr MK, Welter J, Sell W, et al. Sensor-controlled scalp cooling to prevent chemotherapy-induced alopecia in female cancer patients. Current Oncology. 2016;23(6),e576.
104. Katz A. Scalp cooling: The prevention of chemotherapy-induced alopecia. Clinical Journal of Oncology Nursing. 2017;21(4),413-415.
105. Van den Hurk C, Keizer-Heldens P, Raats I, et al. Improving information provision on chemotherapy-induced alopecia and scalp cooling: A comprehensive approach including a website and web-based decision tool. Asia-Pacific Journal of Oncology Nursing. 2019;6(4), 336-342.
106. Shin H, Jo SJ, Kim DH, et al. Efficacy of interventions for prevention of chemotherapy-induced alopecia: A systematic review and meta-analysis. International Journal of Cancer. 2015;136(5),E442-E454.
107. Haque E, Alabdaljabar MS, Ruddy KJ, et al. Management of chemotherapy-in-

duced alopecia (CIA): A comprehensive review and future directions. Critical Reviews in Oncology/Hematology. 2020;156,103093.
108. Nangia J, Wang T, Osborne C, et al. Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial. JAMA. 2017;317(6),596-605.
109. Stoehr JR, Choi JN, Colavincenzo M, et al. Off-label use of topical minoxidil in alopecia: A review. American Journal of Clinical Dermatology. 2019;20(2),237-250.
110. Soleimani MA, Bahrami N, Yaghoobzadeh A, et al. Sexual distress and sexual function in a sample of Iranian women with gynecologic cancers. European Journal of Oncology Nursing. 2018;35, 47-53.
111. Fahami F, Savabi M, Mohamadirizi S, et al. Relationship between sexual dysfunction and treatment modality in patients with gynecologic and breast cancers. The Iranian Journal of Obstetrics, Gynecology and Infertility. 2014;17(116),15-22.
112. Avras M, Tokgözoğlu N. Jinekolojik Onkoloji Cerrahisinde Hipec Tedavisinin Yeri. Türk Jinekolojik Onkoloji Dergisi. 2014;17(1),1-7.
113. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354,34–43.
114. Riggs MJ, Pandalai PK, Kim J, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. Diagnostics. 2020;10(1), 43.
115. Zhang G, Zhu Y, Liu C, et al. The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: The meta-analysis. J Ovarian Res. 2019;12(1), 33.
116. Held-Warmkessel J. Looking into hyperthermic intraperitoneal chemotherap. Nursing. 2015;45(1),65.
117. Dell DD, Held-Warmkessel J, Jakubek P, et al. Care of the open abdomen after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies. Oncology Nursing Forum. 2014;41,4,438-441.
118. Hübner M, Kusamura S, Villeneuve L, et al. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations—Part I: Preoperative and intraoperative management. European Journal of Surgical Oncology. 2020;46(12), 2292-2310.